Role of epsilon amino caproic acid in the management of haemophilic patients with inhibitors.
about
Haematology research in India: past, present and future.Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited.Solulin increases clot stability in whole blood from humans and dogs with hemophilia.Application of current knowledge to the management of bleeding events during immune tolerance induction.Options for treating acute bleeds in addition to bypassing agents: extracorporeal immunoadsorption, FVIII/FIX, desmopressin and antifibrinolytics.Novel therapeutic approaches for haemophilia.Management of Haemophilia in Developing Countries: Challenges and Options.Hemostasis research in India: past, present, and future.Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors.Treatment of refractory hemorrhage with Factor XIII in a patient with hemophilia A with inhibitor.A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors.Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A--a two-centre experience.New coagulant agent (ankaferd blood stopper) for open hemorrhages in hemophilia with inhibitor.High dose factor VIIa improves clot structure and stability in a model of haemophilia B.Trehalose and 6-aminohexanoic acid stabilize and renature glucose-6-phosphate dehydrogenase inactivated by glycation and by guanidinium hydrochloride.
P2860
Q35106402-55578B20-8B64-4ADC-91D2-4DF14E63C289Q35690807-4C47E4CD-3575-4F6E-ACF5-EF5B8811EAEEQ35885322-AAB160BE-103A-416D-9D58-FA4D462FB009Q36643874-DB785EB5-F8DD-4373-8880-181EE630E1EAQ36661839-D778F72D-B8CD-4E36-8699-8E56E3EABE53Q38293116-6DA566D5-43CC-4703-BF5A-36B5639CC248Q38378766-1CB6ED48-3AC7-41BB-93DB-872841E61604Q39022458-85A35E2A-D6CA-4DB0-982E-E170957B32F4Q44211358-91F517BF-4449-487D-AA51-12F3150E731AQ44251818-D4001CBB-2384-4A74-BA92-E0A553C6B0D6Q45868043-C986DC47-CB89-4933-AD87-6FD59FD04217Q45877251-0EAAF010-1A1C-4DC2-A06B-281E369F2AABQ45886126-2168E5BB-FBC7-43C3-834C-11F364220604Q45889198-F3E7DAF4-1C4D-410D-856F-84A20938A424Q46447820-F9D0F757-1FD4-4C61-8F0B-72C269980C7B
P2860
Role of epsilon amino caproic acid in the management of haemophilic patients with inhibitors.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Role of epsilon amino caproic ...... ilic patients with inhibitors.
@en
Role of epsilon amino caproic ...... ilic patients with inhibitors.
@nl
type
label
Role of epsilon amino caproic ...... ilic patients with inhibitors.
@en
Role of epsilon amino caproic ...... ilic patients with inhibitors.
@nl
prefLabel
Role of epsilon amino caproic ...... ilic patients with inhibitors.
@en
Role of epsilon amino caproic ...... ilic patients with inhibitors.
@nl
P2093
P2860
P1433
P1476
Role of epsilon amino caproic ...... ilic patients with inhibitors.
@en
P2093
P2860
P356
10.1046/J.1351-8216.2003.00839.X
P577
2004-01-01T00:00:00Z